据英国研究者报道，Sobering－Plough公司的咪吐三连氮衍生物替莫娃胺（temozolomi）的一项I期临床评估证实，本品可用于儿童高度星形细胞瘤和脑干胶质瘤。在这一I期临床研究中，20例年龄为4～18岁的恶性癌症青少年病人口服本品，每28天连续用药5天。剂量限制性毒性为骨髓抑制 According to a British investigator, a Phase I clinical evaluation of the Tepoting-Plough company’s temozolomi, which is a derivative of the mitimurazine derivative, confirms that this product can be used for highly astrocytomas and brain stem gliomas in children. . In this Phase I clinical study, 20 young adolescents with malignant cancer aged 4 to 18 years were given oral administration of this product, and they were continuously administered for 5 days every 28 days. Dose-limiting toxicity for myelosuppression